Investment Thesis
Marker Therapeutics is a pre-revenue stage biopharmaceutical company burning cash at an unsustainable rate with severe profitability challenges and declining revenue. The company's operating losses of -$12.9M against only $3.5M in revenue, combined with negative free cash flow of -$12.1M, indicate fundamental business execution issues that cannot be sustained.
Strengths
- Strong liquidity position with $16.1M in cash representing 84% of total assets
- Minimal debt burden with zero long-term debt and favorable 8.39x current ratio
- Stockholders' equity of $16.8M provides some balance sheet cushion
Risks
- Revenue declining 46.2% YoY while operating losses remain extremely high, indicating accelerating business deterioration
- Negative free cash flow of -$12.1M annually will deplete the $16.1M cash balance within approximately 16 months at current burn rate
- Pharmaceutical development stage company with no clear path to profitability; no gross margin data suggests product commercialization challenges or lack of marketed products
- Operating margin of -363.5% and net margin of -343.0% represent unsustainable economics requiring significant revenue growth or cost restructuring
- No insider buying activity in last 90 days suggests lack of confidence from management in near-term prospects
Key Metrics to Watch
- Quarterly cash burn rate trend and months of runway remaining
- Revenue trajectory - stabilization or further decline in top-line
- Operating expense structure and ability to reduce burn while advancing pipeline
- Clinical trial progress and partnerships that could validate business model
- Cash position and need for capital raise at potentially unfavorable terms
Financial Metrics
Revenue
3.5M
Net Income
-12.2M
EPS (Diluted)
$-0.79
Free Cash Flow
-12.1M
Total Assets
19.1M
Cash
16.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-363.5%
Net Margin
-343.0%
ROE
-72.4%
ROA
-63.8%
FCF Margin
-341.6%
Balance Sheet & Liquidity
Current Ratio
8.39x
Quick Ratio
8.39x
Debt/Equity
0.00x
Debt/Assets
11.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-02T06:04:11.894076 |
Data as of: 2025-12-31 |
Powered by Claude AI